Shares of Alliqua BioMedical, Inc. (NASDAQ:ALQA) were up 5.9% during trading on Wednesday . The stock traded as high as $0.36 and last traded at $0.36. Approximately 603,988 shares changed hands during trading, a decline of 12% from the average daily volume of 682,495 shares. The stock had previously closed at $0.34.

Several analysts have commented on ALQA shares. Zacks Investment Research upgraded shares of Alliqua BioMedical from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a research report on Tuesday, September 12th. HC Wainwright reduced their target price on shares of Alliqua BioMedical from $2.50 to $1.50 and set a “buy” rating for the company in a research note on Tuesday, July 4th. Finally, ValuEngine lowered shares of Alliqua BioMedical from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Alliqua BioMedical has a consensus rating of “Hold” and an average price target of $1.13.

The firm’s 50-day moving average is $0.32 and its 200-day moving average is $0.40. The company’s market cap is $18.04 million.

Alliqua BioMedical (NASDAQ:ALQA) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. Alliqua BioMedical had a negative net margin of 185.30% and a negative return on equity of 107.24%. The company had revenue of $5.52 million for the quarter, compared to analyst estimates of $5.01 million. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. The company’s quarterly revenue was up 23.5% compared to the same quarter last year. Equities analysts anticipate that Alliqua BioMedical, Inc. will post ($0.36) earnings per share for the current year.

Several large investors have recently modified their holdings of ALQA. Renaissance Technologies LLC increased its holdings in shares of Alliqua BioMedical by 54.2% in the 1st quarter. Renaissance Technologies LLC now owns 632,800 shares of the company’s stock worth $319,000 after buying an additional 222,400 shares during the last quarter. KCG Holdings Inc. boosted its stake in shares of Alliqua BioMedical by 777.7% in the 1st quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock valued at $265,000 after purchasing an additional 465,256 shares in the last quarter. Sabby Management LLC boosted its stake in shares of Alliqua BioMedical by 93.7% in the 1st quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock valued at $1,076,000 after purchasing an additional 1,030,652 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its stake in shares of Alliqua BioMedical by 120.3% in the 1st quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock valued at $2,136,000 after purchasing an additional 2,312,000 shares in the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Alliqua BioMedical, Inc. (ALQA) Trading Up 5.9%” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/alliqua-biomedical-inc-alqa-trading-up-5-9/1576484.html.

Alliqua BioMedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.